Recent data show that the use of an insulin sensitizer (pioglitazone) was associated with a lower rate of progression of coronary atherosclerosis than the use of an insulin secretagogue (glimepiride) in patients with type 2 diabetes [24], data that may be interpreted taking into consideration the line of reasoning presented above. The gene discussed is INS; the disease is type 2 diabetes mellitus.